Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting

NEXT STORY
Jerome Zeldis, M.D., Ph.D, Former Chief Medical Officer of Celgene, to Join BioSig Board of Directors – Corrected Version
PREV STORY
Motif Bio to Present Iclaprim Data at ASM Microbe 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

XBiotech Provides Update on Xilonix™ Phase III Programs in US and EU

AUSTIN, Texas, July 22, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation ...

author_avatar
NASDAQ Market News

Coherus BioSciences Reports Fourth Quarter and Full Year 2017 Financial Results

REDWOOD CITY, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today ...

author_avatar
NASDAQ Market News

Direct-Pay Model Works for Specialty Medical Care, according to the President of the Association of American Physicians and Surgeons (AAPS)

TUCSON, Ariz., March 20, 2017 (GLOBE NEWSWIRE) -- While the direct-pay model for medical ...

author_avatar
NASDAQ Market News